-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Despite effective strategies to prevent human immunodeficiency virus (HIV) infection, the number of new infections worldwide still exceeds 5,000 every day
.
Previous studies have shown that daily oral tenofovir disoproxil-emtricitabine fumarate (TDF-FTC)) can provide protection against HIV infection in different populations
The efficacy of oral pre-exposure prophylaxis (PrEP) drugs is directly related to compliance with prescribed doses
.
PrEP drugs that do not require regular or planned oral administration may increase acceptability and protection during the risk period, thereby reducing the risk of HIV infection
Therefore, there is a need for safe and effective long-acting drugs for pre-exposure prevention (PrEP) of HIV infection to increase the options for preventing HIV infection
.
Long-acting injectable Cabotegravir (CAB-LA) is an integrase inhibitor that can inhibit the replication process of retrovirus and block the integration of retrovirus and host chromosome
.
Previous studies have shown that Cabotegravir has strong anti-HIV activity, can protect non-human primates from various types of HIV exposure, and is safe in humans without limiting toxicity
On August 11, 2021, UCLA researchers published a clinical trial paper titled Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women in the New England Journal of Medicine (NEJM)
.
This phase 2b/3 multi-center, randomized, double-blind, double-simulation, active controlled clinical trial compares the injection of Cabotegravir once every 2 months with oral TDF-FTC in men who have sex with men and transgender women who have sex with men The safety and effectiveness of AIDS prevention in China
.
The research team recruited 4566 volunteers (median age 26 years), of which 570 were transgender women (referring to their biological sex as male but self-identified as female), and the rest were men who acted with men
.
These groups are high-risk groups of AIDS
The researchers randomly assigned them 1:1 to receive two regimens.
Half of the people received an injection of Cabotegravir once every two months, and half of them received oral TDF-FTC every day
.
Then, they were followed up for 153 weeks, and HIV testing and safety assessment were performed
81.
4% of participants in the Cabotegravir group and 31.
3% of the participants in the TDF-FTC group reported injection site reactions, but no serious adverse events
.
A total of 52 participants were infected with AIDS, 13 in the Cabotegravir group (infection rate of 0.
The results of this clinical trial show that long-acting Cabotegravir is better than daily oral TDF-FTC in preventing high-risk groups (males and trans women who have sex with men) from being infected with AIDS
Original source:
Original source:Raphael J.
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women leave a message here
